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Abstract
Prostate cancer (PCa) is no exception to the multi-step process of metastasis. As PCa progresses,
changes occur within the microenvironments of both the malignant cells and their targeted site of
metastasis, enabling the necessary responses that result in successful translocation. The majority of
patients with progressing prostate cancers develop skeletal metastases. Despite advancing efforts
in early detection and management, there remains no effective, long-term cure for metastatic PCa.
Therefore, the elucidation of the mechanism of PCa metastasis and preferential establishment of
lesions in bone is an intensive area of investigation that promises to generate new targets for
therapeutic intervention. This review will survey what is currently know concerning PCa
interaction with the extracellular matrix (ECM) and the roles of factors within the tumor and ECM
microenvironments that contribute to metastasis. These will be discussed within the context of
changes in expression and functional heterodimerization patterns of integrins, changes in ECM
expression and reorganization by proteases facilitating invasion. In this context we also provide a
brief summary of how growth factors (GFs), cytokines and regulatory signaling pathways favor PCa
metastasis to bone.
Background
Prostate cancer (PCa) is the second most common malig-
nancy in men worldwide [1]. In the United States for 2003
there are expected to be 220,900 new diagnoses and
approximately 28,900 PCa deaths [2]. Notably, it has
been determined that ~90% of patients with advanced
PCa will develop osseous metastases [3,4]. Similar studies
on PCa patients at autopsy have found ≥ 80% of patients
have established macrometastases involving bone, and of
these bone lesions ≥ 90% will have an osteoblastic pheno-
type [5,6]. The characteristics of clinical presentation with
bone involvement include severe pain, pathologic frac-
tures and spinal cord compression [7]. Typically these
patients have a mean survival time of nine months to one
year [8]. Thus, once PCa metastasizes to the bone it is dif-
ficult to eradicate.
Metastasis requires the interaction of malignant cells with
three distinct microenvironments 1) the primary organ, 2)
the circulation, and 3) the target organ where a metastatic
lesion will develop [9-11]. Both soluble and insoluble
stromal elements within these microenvironments are
involved in the metastatic cascade [11]. Successful metas-
tasis requires that several well-documented steps be fol-
lowed. Initially, angiogenesis must be induced to meet the
nutrient needs of the growing cancer cells and facilitate
removal of toxic waste products [12,13]. The metastatic
cells must then degrade or remodel basement membrane,
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detach from the primary tumor mass and intravasate.
Tumor cells must next survive the stress of vascular trans-
portation and evade host defense mechanisms [12].
Attachment to their preferred site of metastasis may be
either targeted, via tissue-specific microvessel cell adhe-
sion molecules (CAMs) [14,15], or more general in nature
simply allowing the tumor cells to reside in the target tis-
sue long enough to respond to transendothelial soluble
factors from the target organ (Sikes, unpublished data)
[11]. Tumor cells then extravasate into the target organ
parenchyma, where they proceed to proliferate in the new,
supportive microenvironment as micrometastases.
Finally, the micrometastases must induce angiogenesis to
support growth of the new lesion [16].
Despite intensive research efforts very little is known
about the specific mechanism(s) that contribute to the
predominant pattern of PCa metastasis and establishment
of bony lesions (Sikes, unpublished data). Various theo-
ries have been proposed, including venous drainage, lym-
phatic spread, and arterial emboli [5]. One of the oldest,
for example, is based on anatomical juxtaposition of the
veins draining into the lower vertebral column and pelvic
girdle from the testes, penis and prostate gland called
Batson's plexus [17,18]. Data indicate that lymphatic
channels are only capable of transporting metastatic cells
to regional nodes, and further dissemination is carried out
through the vascular system [17,18].
Prior to reaching the circulation for transport to and sub-
sequent re-colonization at a metastatic site, PCa cells must
become motile and detach from the primary tumor and
overcome the barrier of the extracellular matrix (ECM).
Cell locomotion is a coordinated balance between adhe-
sion and detachment of cells through CAMs that occurs
simultaneously with tumor cell-induced remodeling of
ECM [19-21]. Tumor cell adhesion may be modulated by
cytokines and growth factors (GFs) that effect CAM
expression and functional organization [22]. To date at
least 50 CAMs have been identified and are divided into
four major families based on protein structure: 1) the Ig
superfamily, 2) the cadherin family, 3) integrins and 4)
selectins [23]. Additionally, upregulation of matrix-met-
allo proteinases (MMPs) and other protease-receptor
pairs, like protease-activated receptor 1 (PAR1), facilitate
invasion through the basement membrane, providing
necessary access to either the lymphatic or vascular circu-
lations [24].
LNCaP and PC-3 (Table 1) models are the two principal
culture-to-animal systems being used to delineate the spe-
cific mechanisms required for bone metastasis, and will
be the focus of experimental data presented in this review,
unless otherwise stated. Particularly, the LNCaP model of
PCa progression [25-27] gives an opportunity to follow
coordinated changes in integrin expression, usage, and
behavior of PCa cells when exposed to different ECM sub-
strata and stromally-derived soluble factors; and is unique
in that all cell lines vary in metastatic potential but share
a common genetic background. Previous phenotypic [27]
and genotypic [28] characterizations of these cell lines
also revealed their remarkable resemblance to the clinical
progression of human prostate cancer. The goals of this
review are to discuss the current data that point to tumor-
and ECM-derived factors as major contributors of PCa
metastasizing to bone, with specific attention to soluble
and insoluble factors, CAMs and proteases that mediate
PCa cell detachment from the primary tumor, migration
and invasion to and through the ECM. At the end of each
section, we will attempt to briefly integrate what the data
demonstrates in light of key paracrine signaling mecha-
nisms in both the tumor and ECM microenvironments,
and explain how we believe these mechanisms may drive
metastatic PCa progression. The various prostate cancer
cell lines discussed in this review are briefly described in
Table 1.
Table 1: Basic Properties of Prostate Cell Lines.
Cell Line Origin Androgen Responsiveness Tumorigenicity
NbE1.4 [151-154] Normal rat ventral prostate Androgen sensitive None
P69 [148,149] Normal Human prostate Androgen independent Very poor
DU-145 [147] Human brain metastasis Androgen independent High
LNCaP [145] Human lymph node metastasis Androgen sensitive Low
C4-2* [113,144] Human castrated mice Androgen refractory High with bone metastases
VCaP [150] Human bone metastasis Androgen sensitive High
PC-3 [146] Human bone metastasis Androgen independent High
*This cell line was derived from the original co-inoculation of LNCaP and bone stromal cells in mice. References for each cell line are as follows: 
LNCaP (Lymph Node Carcinoma of the Prostate), PC-3 (Prostate Cancer-3), DU-145 (Dura-145), and VCaP (Vertebral-Cancer of the Prostate).Reproductive Biology and Endocrinology 2004, 2 http://www.rbej.com/content/2/1/2
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The extracellular matrix and prostate cancer 
progression
The ECM or basement membrane of most epithelial
sheets is primarily composed of laminin and collagen
type IV (coll IV), as well as other collagen subtypes. In
addition, the ECM also consists of many non-collagenous
molecules such as bone sialoprotein (BSP), osteopontin
(OPN), osteonectin, osteocalcin (OC), fibronectin, vit-
ronectin (VN), and thrombospondin [29]. As PCa
progresses, the expression of many of these components is
up-regulated, down-regulated, or lost all-together. These
differential patterns of expression aid the tumor in ECM
transmigration and ultimately metastasis. For example,
when prostate cells are transformed with the neu onco-
gene, collagen IV is overexpressed in PCa cell lines PC-3
and NbE1.4 [30,31]; while laminin alone is up-regulated
in NbE1.4 [31] and the calcium-independent intercellular
cell adhesion molecule-7 (ICAM-1) is down-regulated in
PC-3 cells [30]. In the LNCaP progression model, BSP
[32,33], OPN [34] and OC [35] are overexpressed in the
more aggressive C4-2 cells. Multiple studies have also
demonstrated changes in expression of ECM molecules in
advanced PCa tumor samples, such as increased expres-
sion of BSP and Cadherin 11 [36,37], or decreased coll VII
expression [38]. Xue et al., found an interesting pattern of
expression in Tenascin-C, a molecule involved in stromal-
epithelial interactions, where low and moderate-grade
tumors showed high levels of the glycoprotein that dimin-
ished in high-grade tumors [39]. In the same study, they
also documented a dramatic loss of laminin expression
indicating a break in the basement membrane adjacent to
the tumor cells. These findings were recently corroborated
by Brar and colleagues [40].
Cadherins and prostate cancer progression
Cadherins include a multigene family of cell surface adhe-
sion glycoproteins, that provide homotypic interactions
between cells and are used to maintain cell:cell associa-
tions or mediate cell migration [41]. Classical cadherins
(E-, N-, and P-cadherin) possess a highly conserved and
characteristic cytoplasmic domain that interacts with their
functional partners, β- or γ- and α-catenin [42]. Loss of
expression of either pair in this functional complex has
been associated with an invasive phenotype due to
reduced cell:cell adhesion [43-45]. E-cadherin is an epi-
thelial-specific, calcium dependent CAM that functions to
maintain epithelial sheet integrity [46]. As carcinomas
become more aggressive with propensity to metastasize,
E-cadherin is often lost [46], making it a good candidate
to be a metastasis suppressor. It may also serve as a useful
prognostic marker for PCa because it is lost with increas-
ing tumor grade and stage [47,48], and down-regulated in
PCa cell lines, PC-3, LNCaP and C4-2 [37,49,50]. The
nature of the down-regulation is by both protein level and
proteolysis resulting in loss of function. Conversely, the
expression of N-cadherin in PC-3 cells [49] and advanced
prostatic carcinomas [37] has been demonstrated to
increase. This would be expected because N-cadherin
expression in highly invasive breast cancers was found to
replace E-cadherin in facilitating cell:cell contacts, and
thought to mediate the interaction between mammary
tumor and stromal cells [51]. It is therefore thought to
contribute to metastasis via mammary stroma migration
[52], and may function similarly in PCa.
In addition to classical cadherins, Bussemakers et al.,
found other cadherins, including -4, -6, and cadherin-11
were also expressed in a number of PCa cell lines such as
PC-3 [37]. In particular, they found an increased expres-
sion of cadherin-11 and one of its splice-variants, previ-
ously associated with dominant-negative regulation of
cell adhesion [53], suggesting it plays a role in PCa pro-
gression [37]. Interestingly, they also showed no detecta-
ble mRNA or protein expression of cadherin-11 in the less
aggressive LNCaP cells.
Role of integrins during progression
The expression of CAMs on cancer cells, as well as on
endothelial cells, is not static, but dynamic and strictly
controlled by mediators such as GFs, cytokines/chemok-
ines, and the composition of the ECM [22,54-58]. Cell
behavior decisions, such as decreasing cell-cell and cell-
substrate attachment, and increasing cell motility are
accompanied by changes in the expression and/or usage
of adhesion receptors,especially those of the integrin fam-
ily [59,60]. Integrins are themselves heterodimeric mole-
cules, consisting of one α and one β subunit, with at least
20 different combinations already described, many of
which differ in their extra- and intracellular binding spe-
cificities [61,62]. Integrin molecular structure, het-
erodimerization, and intra- and extracellular interactions
with cytoplasmic regulatory proteins and ECM ligands
provide tremendous potential for variation among cell
types, well beyond that available through quantitative var-
iation in integrin expression level alone [63].
Since integrins are intimately involved with cell adhesion
and motility, experiments were performed to see if there
were overt changes in the amount of cell surface integrins
expressed in the LNCaP progression model and P69 cell
lines. Compared to the cancer cell lines, P69 has much
higher expression of integrin subunits (Sikes, unpub-
lished data). These data correspond very well with the
strong binding demonstrated in the adhesion assays and
the low metastatic potential of this SV40-immortalized
cell line (Sikes, unpublished data). Essentially, cells that
adhere too well cannot move well. A direct comparison
between the cell lines of the LNCaP lineage revealed very
few changes in the absolute levels of integrin subunit
expression. Only the α2  and  β5  integrins increasedReproductive Biology and Endocrinology 2004, 2 http://www.rbej.com/content/2/1/2
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appreciably. While α2β1 was shown to bind laminin (LN)
and collagen [64], our previous work [63] indicates that
this integrin pair is probably not utilized in the LNCaP
progression model to bind LN. Integrin α2β1 also medi-
ates PC-3 cell adhesion to collagen I, which is a major
component of the bone matrix [57]; and was found to
mediate cell adhesion to collagen type II, III and IV as well
[65].
Despite the modest changes in the absolute levels of
integrin subunits, we demonstrated that LNCaP and C4-2
cells have switched the functional pairing of integrin het-
erodimers [63]. As described by Edlund et al., LNCaP uses
primarily α6β4 and not β1 pairs to bind LN, VN and OPN,
while C4-2 uses a combination of α3β1 and αvβ3 integrins
to bind these matrix components [63]. This switch in
integrin heterodimer usage reflects a shift from a junc-
tional integrin expression by LNCaP, α6β4, to a motility
associated pair of integrin heterodimers in C4-2 cells, α3β1
and αvβ3. [63]. Additionally, the α6β1 pair is up regulated
in C4-2 cells and has been associated with both an
increase in metastatic behavior and enhanced cell spread-
ing in many prostate cancer cell lines [31,63]. In tissue, an
increase in α6β1 expression was associated with invasion
of the seminal vesicles by prostate cancer [66]. Cooper et
al., demonstrated that the β1 subunit is involved in PC-3
cell adhesion to fibronectin, a soluble ECM component of
the bone microenvironment [67]. These data would tend
to rule out a direct effect of this integrin in the adhesion
of either LNCaP or C4-2 cells, but does not rule out a role
for this pair in cell motility or invasion, especially consid-
ering that the role of β1 in invasion and motility has been
aptly demonstrated for endometrial cancer [68]. Direct
evidence of this in LNCaP and C4-2 remains to be con-
firmed experimentally.
Refocusing on the LNCaP model, the more metastatic
sublines were distinct in their use of αvβ3 and, when com-
pared with parental cells, showed a shift in α6  het-
erodimerization, a subunit critical not only for interaction
with prostate basal lamina but also for interaction with
the bone matrix [63]. The involvement of the αvβ3 pair is
unusual in epithelial cells since it is usually expressed in
lymphocytes and other migratory cell types [69,70]. It is
clear, however, that C4-2 cells are using αvβ3 integrin het-
erodimers for both adhesion and migration on LN, OPN
and VN, while LNCaP cells do not [63,71,72]. Interest-
ingly, breast and lung cancer cell lines that were derived
from bone marrow aspirates also expressed αvβ3, suggest-
ing that it plays a role in overall metastasis of cancer cells
to bone marrow [70]. PCa cell adhesion to and migration
on components present in the bone matrix are also medi-
ated, in part by αvβ3 [73]. For example, a number of stud-
ies have shown that both breast and PCa cells attach to
bone-specific ECM components following transendothe-
lial migration, including vitronectin and osteopontin
[14,22,29,74,75]. The αvβ3 expressed on PCa cells, is also
a natural receptor for many of the previously mentioned
non-collagenous ECM proteins [22,75-77]; and may give
an indication as to why C4-2 cells, known to spontane-
ously relocate to bone [27], increase their use of this
integrin pair as compared to α6β4. It is also relevant to
note here that compared to a number of other PCa cell
lines, αvβ3 expression was recently determined to be the
greatest in PC-3 cells [11]. Thus, the data suggest that
αVβ3, in part, facilitates PCa metastasis to bone by medi-
ating PCa cell adhesion to and migration on OPN and VN,
two dominant proteins in the bone microenvironment
[59].
The mechanism involved in coordinating the heterodimer
usage between these cell lines has not yet been deter-
mined. Curiously, our FACS analysis of live cells would
indicate that the levels of surface α6 and  β4 have not
changed between LNCaP and C4-2. Even-so, α6β4 use
declined in C4-2 cells, in conjunction with an increased
use of α6β1, αvβ3, and α3β1 [63]. This was reiterated by the
observation that the striking increase in the spreading of
C4-2 cells on LN after treatment with stromal factors
could be completely obliterated by the addition of func-
tion-blocking antibodies against α6 or β1, but not against
α2, α3, β4, or αvβ3 [63]. Since α6β4 heterodimers partici-
pate in both the formation of hemidesmosomesas well as
in the control of cell motility by unique properties of the
β4 integrin [78], it is possible that the β4 subunit or α6β4
heterodimer are actively participating in the motility and
invasive behavior of PCa cells in a manner that is different
from that used by LNCaP cells to attach to a substrate. The
function of the β4 integrin would then be determined in a
context-dependent manner interpreting environmental
cues. In primary prostate carcinomas and established PCa
cell lines (DU-145), the α6 integrin subunit maintains a
persistent expression during PCa progression, and shifts
in β subunit heterodimerization partners were observed
from  α6β4 alone to also include α6β1 pairs [38,79]. In
other tumor cell types, these laminin-binding integrins
(α6β4 and α6β1) have also been linked to acquisition of
invasive behaviors [79,80]. The shift in α6 usage concurs
with previous studies, where α6β1 and  α6β4 were both
found in normal prostate cells, but β4 subunit expression
was lost in carcinomas [38,80,81]. Taken together, these
data indicate that functional changes in surface proteins
that are involved in invasion are likely to occur with or
without major changes in levels of the protein expressed
and that these changes are dependent on the epithelial-
ECM-stromal interactions within the tumor and subse-
quent bone microenvironments (Sikes, unpublished
data).Reproductive Biology and Endocrinology 2004, 2 http://www.rbej.com/content/2/1/2
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The data also indicate that human prostate cancer has
altered integrin expression when disseminated to the
bone. When cancer tissue was compared to hyperplastic
or benign tissues, the alterations in integrin usage in can-
cer were found in laminin-binding integrin expression in
particular [74,79,82,83]. For example, a number of stud-
ies showed decreases in the expression of the α6β4 integrin
pair [81], β4 expression alone [84] loss of polarity [85]; as
well as decreased α2, α4, and αv expression [86] in more
advanced PCa tissues as compared to non-invasive sam-
ples. Additionally, Murant et al., found an increase in the
β1 subunit as PCa progresses while Zheng et al., docu-
mented once more the trend of increased expression of
the αvβ3 integrin pair in advanced carcinomas [74,87].
Multiple pathways resulting from extracellular and intrac-
ellular signals regulate invasion of a carcinoma cell.
Indeed, cell migration results from the merging of signal-
ing pathways that employ GFs and their receptors, adhe-
sion receptors (integrins) and cytoskeletal elements [88].
In one investigation, Aprikian et al. demonstrated that
αVβ3 was involved in bombesin, a neurotransmitter and a
cancer growth factor, stimulation of PCa cell motility [89].
Neuroendocrine cells in PCa express and secrete bombe-
sin-like peptides, suggesting that these peptides are
involved in PCa progression [89]. Bombesin increased
PC-3 cell invasion through matrigel, but did not alter its
adhesion to ECM proteins including VN [89]. Addition-
ally, bombesin treatment was found to cause β1, β3, and
β5 integrin subunits to coimmunoprecipitate with focal
adhesion kinase (FAK) [89]. Functions of αvβ3in PCa cells
are mediated by FAK, which activates the phosphatidyli-
nositol 3-kinase (PI-3 kinase)/Akt pathway [74,76]. The
PI3K/Akt pathway may also be involved in androgen-
independent growth of PCa [34,90-94]. Once activated by
an upstream kinase such as FAK, this pathway facilitates
cell survival and proliferation by increasing expression of
the cell cycle regulator E2F, which mediates progression
through the cell cycle; as well as prevents the pro-apop-
totic activity of BAD [95,96]. FAK also activates NF-κB,
which is known to regulate the transcription of anti-apop-
totic proteins [96]. PC-3 cells adhered strongly to collagen
type I, a major component of mineralized bone matrix, in
the presence of TGF-β (10 ng/ml), a growth factor found
in high levels in the bone matrix, and this interaction was
mediated by integrins α3β1 and α2β1 [29,57,97,98]. Kiefer
and Farach-Carson [29] demonstrated that PC-3 cell
adhesion to collagen type I stimulated an increase in cyc-
lin D1 expression followed by an increase in cell division.
This implicates the activation of PI3K, map kinase (ERK1/
2) and p70S6 kinase in the collagen-mediated effect on
PC3 cells.
Changes in extracellular matrix proteases
The ECM is a barrier to a progressing cancer cell at both
the primary and metastatic sites. To overcome the ECM
barrier, cancer cells alter their production of specific pro-
teases that degrade components of the ECM. Changes in
several of these proteases have been associated with pros-
tate cancer progression as described below.
Matrix-metalloproteinases (MMP) are a family of zinc-
dependent endopeptidases with broad substrate specifici-
ties for a variety of ECM/BM components, such as colla-
gen types I, II, III and IV, laminin and fibronectin [99]. As
tumor cells grow and divide, they secrete MMPs that break
down the stroma and basement membrane [11]. At the
same time, there is down-regulation of tissue inhibitors of
MMPs (TIMPs) that amplify the process [100]. In fact,
some members of the MMP family of proteases may asso-
ciate with cell membrane receptors able to drive an ori-
ented degradation of ECM and display a disintegrin
region that, by virtue of an RGD motif, play a role in cell-
cell adhesion and cell migration (ADAM proteinases: A
Disintegrin And Metallo proteinase) [101]. Previous stud-
ies have demonstrated the importance of MMPs associ-
ated with tumor and stroma as critical determinants for
ECM deposition, remodeling and the establishment of
PCa metastases in the bone [20,102,103]. Changes in
expression of specific MMPs are reported to be associated
with PCa progression. Lichtinghagen et al., recently dem-
onstrated that MMP-9 protein was significantly higher in
cancerous prostate tissue compared to normal prostate tis-
sue [104]. There was no significant difference in MMP-2
expression between cancerous and normal tissues; how-
ever, there was a significant difference in the ratios of
MMP-2 and MMP-9 to the tissue inhibitor of metallopro-
teinases 1 (TIMP-1), with cancerous tissue having a higher
ratio. Although MMP-2 protein level is not altered during
prostate cancer progression, an earlier study with prostate
cancer cell lines demonstrated that the expression of
membrane-type 1(MT1)-MMP, which activates proMMP-
2 and is expressed on the surface of invasive cells, is up-
regulated in PC-3 and DU-145 cells [105]. Since the main
component of the basement membrane (BM) is collagen
type IV, a substrate for both MMP-2 and MMP-9, it is con-
ceivable that the higher expression of MMP-9 and MT1-
MMP and the higher ratios of MMP-2 and MMP-9 to
TIMP-1 play important roles in the destruction of the BM
necessary for invasion and metastasis.
Neutral endopeptidase (NEP)-24.11 (neprilysin) is
another cell surface metallopeptidase that may be
involved in prostate cancer progression [106]. NEP
degrades a variety of bioactive peptides including
endothelin, which has been implicated in the growth of
hormone refractory prostate cancer. Usmani et al.,
reported that NEP expression was down-regulated inReproductive Biology and Endocrinology 2004, 2 http://www.rbej.com/content/2/1/2
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advanced prostate cancer cell lines PC-3 and DU145 com-
pared to LNCaP and normal immortalized prostate epi-
thelial cells [106]. Also, NEP expression was down-
regulated in cells derived from malignant tissues taken
from radical prostatectomies compared to those cells
derived from benign prostatic hyperplasia (BPH). We
speculate that the down-regulation of NEP may contrib-
ute to an increase in bioactive peptides required for pros-
tate cancer growth and metastasis
Cathepsins, a family of cysteine proteases capable of
degrading several ECM components including coll IV,
fibronectin and laminin [107-109]; are up-regulated dur-
ing PCa progression. One study showed that the expres-
sion of Cathepsins (Cath) B and S was higher in prostate
cancer tissue compared to BPH and normal prostate tis-
sues; and, they were frequently co-expressed early in the
development of prostate cancer [110]. Sinha et al.,
reported that CathB activity was elevated in prostate can-
cer tissue samples compared to BPH and normal tissue
samples [111]. This study also showed, by biochemical
and immunogold electron microscopic analysis, the asso-
ciation of CathB with the plasma membrane as well as in
lysosomes [111]. Brubaker et al. recently reported that
CathK was expressed in prostate cancer tissues and not in
normal prostate tissues [112]. The expression was variable
in primary prostate cancer samples and soft-tissue metas-
tases, but was consistently elevated in bone metastases.
Surprisingly, CathK expression in PC-3 cell line, which
was derived from a bone metastasis, was low compared to
DU145 (derived from a brain metastasis) and LNCaP
(derived from a lymph node metastasis). Furthermore,
more advanced sublines, C4 and C4-2, of the LNCaP pro-
gression model, demonstrated decreasing expression of
CathK. Note here, the subline C4-2 has a strong tendency
to metastasize to bone in murine hosts [113]. Together
this information demonstrates that Cathepsins contribute
to prostate cancer metastasis and can be up-regulated by
the bone microenvironment, a preferred site of metastasis.
The activation of protease-activated receptor 1 (PAR1;
thrombin receptor) by thrombin may stimulate prostate
cancer cells to secrete MMPs [11,24]. Chay et al., showed
that PAR1 expression was up-regulated in PCa compared
with normal prostate tissue. This overexpression was very
pronounced in bone-derived PCa cell lines (VCaP and
PC3) compared with soft tissue PCa cell lines (DUCaP,
DU145, and LNCaP), suggesting the PAR1, like CathK, is
up-regulated by stromal factors in the bone marrow
[11,24]. Currently, little is known about the role of PAR1
in prostate cancer progression and studies are underway
to determine the effect of PAR1 stimulation on MMP-9
expression in prostate cancer cells. The exact function of
PAR1 expression and thrombin in PCa metastasis has also
not been delineated; however, these data suggest that
PAR1 enhanced expression on bone-derived PCa cells
may be important in targeting these cells to the bone [11].
The urokinase-like plasminogen activator receptor (u-
PAR) is a membrane-associated serine protease receptor
for urokinase or the urokinase plasminogen activator (u-
PA). U-PAR is a three-domain molecule. Each domain is
numbered 1 to 3 from the amino-terminus to the carboxy-
terminus. Domain 1 is the only domain involved in (pro)-
u-PA binding, domain 3 also participates in providing the
u-PA binding site. The receptor (u-PAR/CD87) focuses the
enzymatic activity of u-PA and allows activation of plas-
minogen (PG) at the cell surface, which in turn, is bound
to the cell membrane by α-enolase receptors [114] or to
other cell surface proteins endowed with C-terminal lysyl
residues, and to plasmin (PL) [101]. PL, a serine protein-
ase, similar to trypsin, acts almost exclusively when asso-
ciated with the plasma membrane, because only in that
location is it resistant to its inhibitor, α 2-antiplasmin
[101]. Plasmin is the main protease involved in (pro)-u-
PA activation, which gives origin to the initiation of the
classical protease cascade (plasmin, interstitial MMPs,
MT1-MMP, Gelatinase A) leading to ECM degradation.
Three extracellular protein ligands involved in ECM deg-
radation and cell adhesion have been identified for u-
PAR, namely u-PA, vitronectin (VN), and kininogen. VN
and the two-chain form of high molecular weight kinino-
gen (HMWK) share overlapping and mutually exclusive
binding sites for u-PAR domains 2 and 3. HMWK-bound
kallikrein (kall) may activate the conversion of u-PAR-
bound (pro)-u-PA to u-PA, thus providing an alternate
pathway to the one triggered by plasmin to (pro)-u-PA
activation. Many indications suggest that the u-PA/u-PAR
system, together with specific inhibitors of plasminogen
activators (PAIs), is an organizer of cell-ECM contacts and
covers the full range of activities required to promote and
disrupt cell attachment sites [115]. PC-3 and C4-2 secrete
more u-PA than LNCaP cells [116,117], which is most
notably involved in the regulation of ECM-laminin degra-
dation, thereby allowing for PC-3 and C4-2 cells to
behave more aggressively. Indeed, in a later study con-
ducted by Festuccia et al., the malignant phenotype of PCa
cells (LNCaP, C4-2, PC-3 and DU-145) was correlated
with both u-PA and u-PAR expression [118]. They found
that differential production of u-PA corresponded with
the ability of the more aggressive lines to bind and activate
plasminogen; thus providing direct support that u-PA
secretion and the levels of u-PA- u-PAR complexes charac-
terize the invasive phenotype of these cells [118]. These
blocking antibody experiments also provided evidence
that this pattern of expression correlates with stage and
grade in prostatic carcinomas, making u-PA or plasmin
candidate target molecules for metastasis-inhibiting
therapeutics.Reproductive Biology and Endocrinology 2004, 2 http://www.rbej.com/content/2/1/2
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Several other molecules interact 'constitutively' with u-
PAR domains 2 and/or 3, thereby functioning as 'corecep-
tors'. These molecules include the α2-macroglobulin
receptor/low density lipoprotein receptor-related protein
(α2MR/LRP), the mannose-6-phosphate receptor
(Man6PR)/ IGFII-receptor, gp130, u-PAR-associated pro-
tein (u-PARAP) and integrins [101]. Integrin family mem-
bers including β1,  β2 and  β3, may interact with u-PAR
domains 2 and 3 as u-PAR co-receptors, which leads to an
enfeeblement of integrin-ECM interactions [119]. If the
cell expresses low or no caveolin, u-PAR-integrin com-
plexes remain loose, floating on unspecialized areas of the
cell membrane, integrin function will be impaired, and
the cell-ECM interaction will rely solely on adhesive inter-
actions mediated by u-PAR-VN [120]. This seems to be the
case for leukocytes and transformed cells, where the
motile properties of the cell must prevail on the cell-ECM
moorings. On the contrary, if the cells express high levels
of caveolin, u-PAR, as with many other GPI-anchored pro-
teins, form clusters on caveolin-rich membrane rafts,
together with the loose integrins. In this case, the complex
"signalosome" of caveolae, rich in kinases of the src fam-
ily, transduce signals leading to integrin overexpression,
which reinforces cell-ECM interactions. This situation has
been recognized in macrophages and metastatic tumor
cells and results in enhanced adhesion and migration on
ECM components [101]. The end result of the involve-
ment of such a large range of signaling molecules is the
activation of several groups of intracellular kinases such as
Src, Src-like protein kinases (Hck and Fgf) and again FAK
with convergence on the extracellular regulated kinase
(ERK)1/2 pathway [121].
Summary and conclusions
The expression of CAMs on tumor cells is not static, but
dynamic, and is regulated strictly by extracellular cues like
soluble GFs, cytokines, and the insoluble proteins com-
posing the ECM [54-58,122,123]. Although a number of
integrin variations during PCa cell progression have been
described [38,74,79-81,124-126], neither modulation of
these variations by external factors nor integrin het-
erodimer usage regulation is well understood [63].
"Inside-out" regulation of integrin heterodimer activity
and subunit partner choices are thought to depend on
unique cytoplasmic regulatory protein repertoires that dif-
fer among host cell types [127-130]. Likewise, "outside-
in" regulation by integrins, in response to extracellular
cues, has revealed shifts in integrin gene expression as well
as changing integrin associations with numerous signal-
ing molecules,including protein tyrosine kinases (FAK
and pp60src), serine kinases (protein kinase C, extracellu-
lar signal-regulated kinase, c-Jun-NH2-terminal kinase,
and integrin-linked kinase), and lipid intermediates (PI3K
and phosphatidylinositol 4,5-kinase) [62,131-133].
Hence, integrin activity within a given cell is tightly coor-
dinated with its cell cycle, gene expression profiles, differ-
entiation, and cell survival [61]. In our studies, few shifts
in integrin expression were found to accompany PCa dis-
ease progression, while integrin heterodimer usage,
changed significantly [63]. Changes in integrin expression
or the functional reassortment of the heterodimers as a
tumor progresses has been studied in both the PC-3 and
LNCaP PCa cell line models but the mechanism has not
been elucidated.
The final component to this story includes the protease-
receptor complexes, which are also molecular organizers
of cell-to-ECM interactions. They coordinate both adhe-
sive and degradative activities necessary to facilitate meta-
static progression [101]. Because traversing the ECM is a
critical step in the invasive process, it is imperative that the
mechanisms driving the conversion of stationary tumor
cells to ones with the capacity to migrate be elucidated.
Various cell-associated serine proteases and their respec-
tive receptors have been shown to up-regulate u-PAR, giv-
ing the u-PA/u-PAR/PAI-1 system prognostic significance
in several tumor types [101], including PCa. As informa-
tion about which u-PAR domains and u-PA sequences
specifically mediate malignant invasion via proteolysis
and adhesion increases, the likelihood of improved
rational drug development to control the factors of the
fibrinolytic system should also increase.
Integrin regulation of prostate epithelial proliferation is
likely to involve interactions between these CAMs and GF
receptors [63]. Such interactions are used by cells to inter-
pret positive and negative GF and cytokine signals from
surrounding stromal cells [134,135], via common signal-
ing cascade components (e.g., small GTPases), also
important for integrin signaling and activation. Preferen-
tial associations between the GF receptors and the chang-
ing integrin heterodimers could have dramatic
consequences on the responses of a cell to environmental
cues [63]. In LNCaP cells, α6β4, is very important for
attachment and would tend to restrict cell migration;
while α6β1 and α3β1, both of which are involved in the
formation of dynamic focal contacts cycled during migra-
tion, are important for cell locomotion [79]. In C4-2 cells,
spreading in response to stromal factors appears to be
mediated through α6β1 which, along with αvβ3 are respon-
sible for migration [63]. Similarly, we found the α6β1 het-
erodimer to be more involved in cell spreading than static
cell attachment in either neu-transformed cells or the
LNCaP progression model [31,63]. The ability of α3β1 to
alter laminin chains and overall basement membrane
architecture [136,137] is particularly suggestive, given that
proteolytic cleavage of laminin can drive cells from static
adhesion to active migration [138,139]. Although β1 was
shown not to be responsible for PC-3 cell invasion, it may
still play a role in C4-2 cell migration/invasion [140].Reproductive Biology and Endocrinology 2004, 2 http://www.rbej.com/content/2/1/2
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Most notably, the majority of these functions are directed
by α6β4 in LNCaP, suggesting that a functional reassort-
ment of integrins occurs coincident with the acquisition
of additional metastatic traits by C4-2 [140]. Not fre-
quently found in epithelial cells, αvβ3 is common to a
number of bone metastases, including those of prostate
and breast carcinomas [74,126,141]. Two possible conse-
quences of αvβ3  heterodimer usage in the metastatic
LNCaP sublines are (a) preferential relocation to the bone
and (b) increased cell survival/suppressed cell death [63].
Outside of the role of αvβ3 in binding metastatic cells to
the bone matrix, this integrin heterodimer is also a good
candidate regulator of cell survival in the absence of cell
adhesion [63], and thus will remain in the focus of tar-
geted anti-invasive therapies. Although loss of appropri-
ate adhesion is normally a cue for apoptosis, human
breast cancer cells are able to use αvβ3 to inhibit p53 activ-
ity and suppress the bax death pathway [142]. Accord-
ingly, αvβ3 has been shown to regulate cell proliferation in
prostate epithelia [143]. The various patterns of differen-
tial expression of ECM molecules, proteases and integrins
discussed in this review have been summarized in Table 1.
One of the most notable trends in the area of PCa metas-
tasis is the move towards more complicated in vitro and in
vivo systems. This has become necessary since it is now
apparent that studying the individual components,
prostate or bone cells, or other components of their
microenvironments alone, is clearly deficient. These cells
alter their gene expression and migratory behavior in
Table 2: Summary of Molecular Changes Associated with Prostate Cancer Metastasis
Cell line ECM Proteases Integrins
VcaP ↑ PAR [24] ↑αVβ3 [11]
PC-3→PC-3(Neu-T) ↑ CollIV [30] ↑ PAR [24] ↑αVβ3 [11]
PC-3M ↓ ICAM-1 [30] ↑ MT1-MMP [105]
↑ N-Cadherin [49] ↓ NEP [156] ↑α2β1 [97]
↓ E-Cadherin [49] ↑ Cathepsin D [157,158]
↑ Cadherin 11 [37] ↑ uPA [116]
DU-145
↑ MT1-MMP [105]
↑ MMP-9 [159]
↓ NEP [156]
uPA [116]
LNCaP→C4-2 ↑ OSC [32] ↑ uPA [116] ↑α3β1 (usage) [63]
↑ OPN [27] ↑ PSA [34] ↑α1 (usage) [63]
↑ BSP [32] Cathepsin D (LNCaP) [157,158] ↑αVβ3 (usage) [63]
E-Cadherin [155] ↓α6β4 [63]
↑α2 [63]
↑α6β1 [63]
NbE1.4 (Neu-T)
↑ Laminin [31]
↑ CollIV [31] ↑α6β1 [31]
Tissues
Benign→Malignant ↑ BSP [160] ↑ Cathepsin BA [110,111] ↑β1 subunit [87]
↑ Cadherin 11 [37] ↑ Cathepsin S [110] ↓α6β4 [81]
↑ N-Cadherin [49] ↑ MMP9 [104] ↑αVβ3
↓ E-Cadherin [87] ↑ Cathepsin K "bone" [112] ↓β4 [84]
↓ Laminin [40] ↑ HK2 [161] ↓β4 (loss polarity) [85]
↑ Tenascin C [39] ↑ MMP2 [162] ↓α2 [86]
↓ Collagen VII [81] ↑ MMP7 [163] ↓α4 [86]
↓ TIMP1 [163] ↓αV [86]
↑ Cathepsin D [164]
↑ MMP26 165
VCaP, PC-3, and DU-145 are advanced prostate cancer cell lines and were compared to the less advanced LNCaP cell line. The information under 
cell lines reflects this comparison. Please note the following: "bone" refers to observations specific for the bone-derived cell lines or malignant tissue 
from the bone, ↑ refers to an increase expression and ↓ refers to a decrease expression, OSC refers to osteocalcin, OPN refers osteopontin, 
superscript A refers to increased activation, MMP is matrix-metalloproteinase and LNCaP→C4-2 refers to LNCaP progression to androgen-
independent C4-2 subline.Reproductive Biology and Endocrinology 2004, 2 http://www.rbej.com/content/2/1/2
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response to co-culture or cross-feeding (personal commu-
nication Dr. Farach-Carson). Furthermore, the only way
to effectively resolve the role of tumor versus ECM factors
in the migration and downstream establishment of boney
metastases will be to examine the behavior of these vari-
ous cells types in structured mutlicellular assays. Candi-
date target proteins can be down regulated using
antibodies, ribozymes or RNAi. Conversely critical pro-
teins can be supplemented to systems of reduced com-
plexity to test for the biological response or re-expressed
in tumor cells to study the effects of their expression. The
individual cells can be followed using fluorescent tags to
visualize cell interactions. Once established, these models
will allow for the functional analysis of ECM proteins,
proteases and integrins involved in the dynamic journey
of PCa cells from their site of origin to their interaction
with factors and cells from the bone milieu that include
ECM, stroma, osteoblasts and osteoclasts, to ultimately
colonize the bone.
Acknowledgments
The authors gratefully acknowledge Dr. Mary C. Farach-Carson for her 
invaluable discussions on prostate: bone interactions and for critical reading 
of this manuscript. This work was supported by the prostate cancer 
research program grant DAMD17-00-1-0049 (RAS), NIH DK/ES59146 
(RAS), NIH 1K22CA97117-01 (CRC) and start-up funds from the Univer-
sity of Delaware (RAS/CRC).
References
1. Parkin DM, Pisani P, Ferlay J: Global Cancer Statistics. CA Cancer
Journal Clinicians 1999, 49:33-64.
2. Jemal A, Murray T, Samuels A, Ghafoor A, Ward E, Thun MJ: Cancer
statistics, 2003. CA Cancer J Clin 2003, 53:5-26.
3. Rubin MA, Putzi M, Mucci N, Smith DC, Wojno K, Korenchuk S,
Pienta KJ: Rapid ("warm") autopsy study for procurement of
metastatic prostate cancer. Clin Cancer Res 2000, 6:1038-1045.
4. Bubendorf L, Schopfer A, Wagner U, Sauter G, Moch H, Willi N, Gas-
ser TC, Mihatsch MJ: Metastatic patterns of prostate cancer: an
autopsy study of 1,589 patients. Hum Pathol 2000, 31:578-583.
5. Jacobs SC: Spread of prostatic cancer to bone. Urology 1983,
21:337-344.
6. Koutsilieris M: Skeletal metastases in advanced prostate can-
cer: cell biology and therapy.  Crit Rev Oncol Hematol 1995,
18:51-64.
7. Rubens RD: Bone metastases-the clinical problem. Eur J Cancer
1998, 34:210-213.
8. Cheville JC, Tindall D, Boelter C, Jenkins R, Lohse CM, Pankratz VS,
Sebo TJ, Davis B, Blute ML: Metastatic prostate carcinoma to
bone: clinical and pathologic features associated with can-
cer-specific survival. Cancer 2002, 95:1028-1036.
9. Radinsky R, Fidler IJ: Regulation of tumor cell growth at organ-
specific metastases. In Vivo 1992, 6:325-331.
10. Mundy GR: Mechanisms of bone metastasis.  Cancer 1997,
80:1546-1556.
11. Cooper CR,, Chay CH, Gendernalik JD, Lee H-L, Bhatia J, Taichman
RS, McCauley LK, Keller ET, Pienta KJ: Stromal factors involved
in prostate carcinoma metastasis to bone.  Cancer 2003,
97:739-747.
12. Gopalkrishnan RV, Kang DC, Fisher PB: Molecular markers and
determinants of prostate cancer metastasis. J Cell Physiol 2001,
189:245-256.
13. Ellis LM, Fidler IJ: Angiogenesis and metastasis. Eur J Cancer 1996,
32A:2451-2460.
14. Cooper CR, Pienta KJ: Cell adhesion and chemotaxis in pros-
tate cancer metastasis to bone: a minireview. Prostate Cancer
Prostatic Dis 2000, 3:6-12.
15. Lehr Jeffrey E., Pienta Kenneth J.: Preferential adhesion of pros-
tate cancer cells to a human bone marrow endothelial cell
line. Journal of the National Cancer Institute 1998, 90:118-123.
16. Chay Christopher H., Cooper Carlton R., Hellerstedt Beth A., Pienta
Kenneth J.: Antimetastatic drugs in prostate cancer. Clinical
Prostate Can 2002, 1:14-19.
17. Batson OV: The vertebral system of veins as a means for can-
cer dissemination. Prog Clin Cancer 1967, 3:1-18.
18. Batson OV: The function of the vertebral veins and their role
in the spread of metastases. Clin Orthop 1995, 1940:4-9.
19. Holly SP, Larson MK, Parise LV: Multiple roles of integrins in cell
motility. Exp Cell Res 2000, 261:69-74.
20. Hornebeck W, Emonard H, Monboisse JC, Bellon G: Matrix-
directed regulation of pericellular proteolysis and tumor
progression. Semin Cancer Biol 2002, 12:231-241.
21. Condeelis JS, Wyckoff JB, Bailly M, Pestell R, Lawrence D, Backer J,
Segall JE: Lamellipodia in invasion.  Semin Cancer Biol 2001,
11:119-128.
22. Cooper CR, Bhatia JK, Muenchen HJ, McLean L, Hayasaka S, Taylor J,
Poncza PJ, Pienta KJ: The regulation of prostate cancer cell
adhesion to human bone marrow endothelial cell monolay-
ers by androgen dihydrotestosterone and cytokines. Clin Exp
Metastasis 2002, 19:25-33.
23. Okegawa T, Li Y, Pong RC, Hsieh JT: Cell adhesion proteins as
tumor suppressors. J Urol 2002, 167:1836-1843.
24. Chay Christopher H., Cooper Carlton R., Gendernalik James D.,
Dhanasekaran Saravana M., Chinnaiyan Arul M., Rubin Mark, Schmaier
Alvin H., Pienta Kenneth J.: A functional thrombin receptor
(PAR1) is expressed on bone-derived prostate cancer cell
lines. Urology 2002, 60:760-765.
25. Chung LW, Kao C, Sikes RA, Zhau HE: Human prostate cancer
progression models and therapeutic intervention. Hinyokika
Kiyo 1997, 43:815-820.
26. Wu HC, Hsieh JT, Gleave ME, Brown NM, Pathak S, Chung LW: Der-
ivation of androgen-independent human LNCaP prostatic
cancer cell sublines: role of bone stromal cells. Int J Cancer
1994, 57:406-412.
27. Thalmann George N., Anezinis Ploutarchos E., Chang Shi-Ming, Zhau
Haiyen E., Kim E. Edmund, Hopwood Vicki L., Pathak Sen, Eschenbach
Andrew C. von, Chung Leland W. K.: Androgen-independent
cancer progression and bone metastasis in the LNCaP
model of human prostate cancer.  Cancer Res 1994,
54:2577-2581.
28. Hyytinen ER, Thalmann GN, Zhau HE, Karhu R, Kallioniemi OP,
Chung LW, Visakorpi T: Genetic changes associated with the
acquisition of androgen-independent growth, tumorigenicity
and metastatic potential in a prostate cancer model. Br J
Cancer 1997, 75:190-195.
29. Kiefer JA, Farach-Carson MC: Type I collagen-mediated prolifer-
ation of PC3 prostate carcinoma cell line: implications for
enhanced growth in the bone microenvironment. Matrix Biol
2001, 20:429-437.
30. Zhau HY, Zhou J, Symmans WF, Chen BQ, Chang SM, Sikes RA,
Chung LW: Transfected neu oncogene induces human pros-
tate cancer metastasis. Prostate 1996, 28:73-83.
31. Vafa A, Zhang Y, Sikes RA, Marengo SR: Overexpression of
p185erbB2/neu in the NbE prostatic epithelial cell line
increases cellular spreading and the expression of integrin
alpha6beta1. Int J Oncol 1998, 13:1191-1197.
32. Koeneman KS, Yeung F, Chung LW: Osteomimetic properties of
prostate cancer cells: a hypothesis supporting the predilec-
tion of prostate cancer metastasis and growth in the bone
environment. Prostate 1999, 39:246-261.
33. Lin CC, Lu YP, Lou YR, Ho CT, Newmark HH, MacDonald C, Single-
tary KW, Huang MT: Inhibition by dietary dibenzoylmethane of
mammary gland proliferation, formation of DMBA-DNA
adducts in mammary glands, and mammary tumorigenesis
in Sencar mice. Cancer Lett 2001, 168:125-132.
34. Thalmann GN, Sikes RA, Devoll RE, Kiefer JA, Markwalder R, Klima
I, Farach-Carson CM, Studer UE, Chung LW: Osteopontin: possi-
ble role in prostate cancer progression. Clin Cancer Res 1999,
5:2271-2277.
35. Chung LW, Zhau HE, Wu TT: Development of human prostate
cancer models for chemoprevention and experimental ther-
apeutics studies. J Cell Biochem Suppl 1997, 29:174-181.Reproductive Biology and Endocrinology 2004, 2 http://www.rbej.com/content/2/1/2
Page 10 of 13
(page number not for citation purposes)
36. Waltregny D, Bellahcene A, Van Riet I, Fisher LW, Young M, Fernan-
dez P, Dewe W, de Leval J, Castronovo V: Prognostic value of
bone sialoprotein expression in clinically localized human
prostate cancer. J Natl Cancer Inst 1998, 90:1000-1008.
37. Bussemakers MJ, Van Bokhoven A, Tomita K, Jansen CF, Schalken JA:
Complex cadherin expression in human prostate cancer
cells. Int J Cancer 2000, 85:446-450.
38. Nagle RB, Hao J, Knox JD, Dalkin BL, Clark V, Cress AE: Expression
of hemidesmosomal and extracellular matrix proteins by
normal and malignant human prostate tissue. Am J Pathol 1995,
146:1498-1507.
39. Xue Y, Li J, Latijnhouwers MA, Smedts F, Umbas R, Aalders TW,
Debruyne FM, De La Rosette JJ, Schalken JA: Expression of perig-
landular tenascin-C and basement membrane laminin in
normal prostate, benign prostatic hyperplasia and prostate
carcinoma. Br J Urol 1998, 81:844-851.
40. Brar PK, Dalkin BL, Weyer C, Sallam K, Virtanen I, Nagle RB: Lam-
inin alpha-1, alpha-3, and alpha-5 chain expression in human
prepubertal [correction of prepubetal] benign prostate
glands and adult benign and malignant prostate glands. Pros-
tate 2003, 55:65-70.
41. Takeichi M: Cadherin cell adhesion receptors as a morphoge-
netic regulator. Science 1991, 251:1451-1455.
42. Kemler R: From cadherins to catenins: cytoplasmic protein
interactions and regulation of cell adhesion. Trends Genet 1993,
9:317-321.
43. Behrens J: Cadherins as determinants of tissue morphology
and suppressors of invasion. Acta Anat 1994, 149:165-169.
44. Behrens J: Cell contacts, differentiation, and invasiveness of
epithelial cells. Invasion Metastasis 1994, 14:61-70.
45. Birchmeier W, Behrens J: Cadherin expression in carcinomas:
role in the formation of cell junctions and the prevention of
invasiveness. Biochim Biophys Acta 1994, 1198:11-26.
46. Takeichi M: Cadherins in cancer: implications for invasion and
metastasis. Curr Opin Cell Biol 1993, 5:806-811.
47. Umbas R, Schalken JA, Aalders TW, al. et: Expression of the cellu-
lar adhesion molecule E-cadherin is reduced or absent in
high-grade prostate cancer. Cancer Res 1992, 52:5104-5109.
48. Murant SJ, Rolley N, Phillips SM, Stower M, Maitland NJ: Allelic
imbalance within the E-cadherin gene is an infrequent event
in prostate carcinogenesis.  Genes Chromosomes Cancer 2000,
27:104-109.
49. Tran NL, Nagle RB, Cress AE, Heimark RL: N-Cadherin expres-
sion in human prostate carcinoma cell lines. An epithelial-
mesenchymal transformation mediating adhesion with Stro-
mal cells. Am J Pathol 1999, 155:787-798.
50. Day ML, Zhao X, Vallorosi CJ, Putzi M, Powell CT, Lin C, Day KC: E-
cadherin mediates aggregation-dependent survival of pros-
tate and mammary epithelial cells through the retinoblast-
oma cell cycle control pathway.  J Biol Chem 1999,
274:9656-9664.
51. Hazan RB, Kang L, Whooley BP, Borgen PI: N-cadherin promotes
adhesion between invasive breast cancer cells and the
stroma. Cell Adhes Commun 1997, 4:399-411.
52. Hagios C, Lochter A, Bissell MJ: Tissue architecture: the ulti-
mate regulator of epithelial function? Phil Trans R Soc London
Series B: Biol Sci 1998, 353:857.
53. Okazaki M, Takeshita S, Kawai S, Kikuno R, Tsujimura A, Kudo A,
Amann E: Molecular cloning and characterization of OB-cad-
herin, a new member of cadherin family expressed in
osteoblasts. J Biol Chem 1994, 269:12092-12098.
54. Pauli Bendicht U., Lee Cho-Lea: Organ preference of metastasis:
The role of organ-specifically modulated endothelial cells.
Laboratory Investigation 1988, 58:379-387.
55. Augustin-Voss HG, Johnson RC, Pauli BU: Modulation of endothe-
lial cell surface glycoconjugate expression by organ-derived
biomatrices. Exp Cell Res 1991, 192:346-351.
56. Haraldsen G, Kvale D, Lien B, Farstad IN, Brandtzaeg P: Cytokine-
regulated expression of E-selectin, intercellular adhesion
molecule-1 (ICAM-1), and vascular cell adhesion molecule-1
(VCAM-1) in human microvascular endothelial cells. Journal of
Immunology 1996, 156:2558-2565.
57. Kostenuik PJ, Singh G, Orr FW: Transforming growth factor
beta upregulates the integrin-mediated adhesion of human
prostatic carcinoma cells to type I collagen. Clin Exp Metastasis
1997, 15:41-52.
58. Khatib AM, Kontogiannea M, Fallavollita L, Jamison B, Meterissian S,
Brodt P: Rapid induction of cytokine and E-selectin expression
in the liver in response to metastatic tumor cells. Cancer Res
1999, 59:1356-1361.
59. Varner JA, Cheresh DA: Tumor angiogenesis and the role of
vascular cell integrin alphav beta3. Important Advances in Oncol-
ogy Edited by: VT DeVita, S Hellman and SA Rosenberg. Philadelphia, Lip-
pincott-Raven Publishers; 1996:66-87. 
60. Albelda SM: Role of integrins and other cell adhesion mole-
cules in tumor progression and metastasis. Lab Invest 1993,
68:4-17.
61. Aplin AE, Howe A, Alahari SK, Juliano RL: Signal transduction and
signal modulation by cell adhesion receptors: the role of
integrins, cadherins, immunoglobulin-cell adhesion mole-
cules, and selectins. Pharmacol Rev 1998, 50:197-263.
62. Schwartz MA, Schaller MD, Ginsberg MH: Integrins: emerging
paradigms of signal transduction. Annu Rev Cell Dev Biol 1995,
11:549-599.
63. Edlund Magnus, Miyamoto Tadayuki, Sikes Robert A., Ogle Roy, Lau-
rie Gordon W., Farach-Carson Mary C., Otey Carol A., Zhau Haiyen
E., Chung Leland W. K.: Integrin expression and usage by pros-
tate cancer cell lines on laminin substrata. Cell Growth Differ
2001, 12:99-107.
64. Hemler ME, Elices MJ, Chan BM, Zetter B, Matsuura N, Takada Y:
Multiple ligand binding functions for VLA-2 (alpha 2 beta 1)
and VLA-3 (alpha 3 beta 1) in the integrin family. Cell Differ Dev
1990, 32:229-238.
65. Rokhlin OW, Cohen MB: Expression of cellular adhesion mole-
cules on human prostate tumor cell lines.  Prostate 1995,
26:205-212.
66. Schmelz M, Cress AE, Scott KM, Burger F, Cui H, Sallam K, McDaniel
KM, Dalkin BL, Nagle RB: Different phenotypes in human pros-
tate cancer: alpha6 or alpha3 integrin in cell-extracellular
adhesion sites. Neoplasia 2002, 4:243-254.
67. Cooper Carlton R., McLean Lisa, Mucci Neil R., Poncza Paul, Pienta
Kenneth J.: Prostate cancer cell adhesion to quiescent
endothelial cells is not mediated by beta-1 integrin subunit.
Anticancer Research 2000, 20:4159-4162.
68. Prifti S, Zourab Y, Koumouridis A, Bohlmann M, Strowitzki T, Rabe
T: Role of integrins in invasion of endometrial cancer cell
lines. Gynecol Oncol 2002, 84:12-20.
69. Eliceiri BP, Cheresh DA: Role of alpha v integrins during
angiogenesis. Cancer J 2000, 6 Suppl 3:S245-9.
70. Cooper CR, Chay CH, Pienta KJ: The role of alpha(v)beta(3) in
prostate cancer progression. Neoplasia 2002, 4:191-194.
71. Seiffert D: Detection of vitronectin in mineralized bone
matrix. J Histochem Cytochem 1996, 44:275-280.
72. Liaw L, Skinner MP, Raines EW, Ross R, Cheresh DA, Schwartz SM,
Giachelli CM: The adhesive and migratory effects of osteopon-
tin are mediated via distinct cell surface integrins. Role of
alpha v beta 3 in smooth muscle cell migration to osteopon-
tin in vitro. J Clin Invest 1995, 95:713-724.
73. Hullinger TG, McCauley LK, Dejoode ML, Somerman MJ: Effect of
bone proteins on human prostate cancer cell lines in vitro.
Prostate 1998, 36:14-22.
74. Zheng DQ, Woodard AS, Fornaro M, Tallini G, Languino LR: Pros-
tatic carcinoma cell migration via alpha(v)beta3 integrin is
modulated by a focal adhesion kinase pathway. Cancer Res
1999, 59:1655-1664.
75. Byzova Tatiana V., Kim Wes, Midura Ronald J., Plow Edward F.: Acti-
vation of integrin avB3 regulates cell adhesion and migration
on bone sialoprotein. Exp Cell Res 2000, 254:299-308.
76. Zheng Duo-Qi, Woodard Amy S., Tallini Giovanni, Languino Lucia R.:
Substrate specificity of avb3 integrin-mediated cell migra-
tion and phosphatidylinositol 3-kinase/AKT pathway
activation. Journal of Biological Chemistry 2000, 275:24565-24574.
77. Pecheur I, Peyruchaud O, Serre CM, Guglielmi J, Voland C, Bourre F,
Margue C, Cohen-Solal M, Buffet A, Kieffer N, Clezardin P: Integrin
alpha(v)beta3 expression confers on tumor cells a greater
propensity to metastasize to bone. FASEB 2002, 16:1266-1268.
78. Mercurio AM, Rabinovitz I: Towards a mechanistic understand-
ing of tumor invasion--lessons from the alpha6beta 4
integrin. Semin Cancer Biol 2001, 11:129-141.
79. Rabinovitz I, Nagle RB, Cress AE: Integrin alpha 6 expression in
human prostate carcinoma cells is associated with a migra-Reproductive Biology and Endocrinology 2004, 2 http://www.rbej.com/content/2/1/2
Page 11 of 13
(page number not for citation purposes)
tory and invasive phenotype in vitro and in vivo.  Clin Exp
Metastasis 1995, 13:481-491.
80. Bonkhoff H, Stein U, Remberger K: Differential expression of
alpha 6 and alpha 2 very late antigen integrins in the normal,
hyperplastic, and neoplastic prostate: simultaneous demon-
stration of cell surface receptors and their extracellular
ligands. Hum Pathol 1993, 24:243-248.
81. Knox JD, Cress AE, Clark V, Manriquez L, Affinito KS, Dalkin BL,
Nagle RB: Differential expression of extracellular matrix mol-
ecules and the alpha 6-integrins in the normal and neoplastic
prostate. Am J Pathol 1994, 145:167-174.
82. Rabinovitz I, Mercurio AM: The integrin alpha6beta4 functions
in carcinoma cell migration on laminin-1 by mediating the
formation and stabilization of actin- containing motility
structures. J Cell Biol 1997, 139:1873-1884.
83. Kitazawa S, Maeda S: Development of skeletal metastases. Clin
Orthop 1995:45-50.
84. von Bredow DC, Nagle RB, Bowden GT, Cress AE: Cleavage of
beta4 Integrin by Matrilysin.  Experimental Cell Res 1997,
236:341-345.
85. Dans M, Gagnoux-Palacios L, Blaikie P, Klein S, Mariotti A, Giancotti
FG: Tyrosine phosphorylation of the beta 4 integrin cytoplas-
mic domain mediates Shc signaling to extracellular signal-
regulated kinase and antagonizes formation of
hemidesmosomes. J Biol Chem 2001, 276:1494-1502.
86. Cress AE, Rabinovitz I, Zhu W, Nagle RB: The alpha 6 beta 1 and
alpha 6 beta 4 integrins in human prostate cancer
progression. Cancer Metastasis Rev 1995, 14:219-228.
87. Murant SJ, Handley J, Stower M, Reid N, Cussenot O, Maitland NJ:
Co-ordinated changes in expression of cell adhesion mole-
cules in prostate cancer. Eur J Cancer 1997, 33:263-271.
88. Bonaccorsi L, Muratori M, Carloni V, Zecchi S, Formigli L, Forti G,
Baldi E: Androgen receptor and prostate cancer invasion. Int J
Androl 2003, 26:21-25.
89. Aprikian AG, Tremblay L, Han K, Chevalier S: Bombesin stimu-
lates the motility of human prostate-carcinoma cells
through tyrosine phosphorylation of focal adhesion kinase
and of integrin-associated proteins.  Int J Cancer 1997,
72:498-504.
90. Miyake H, Nelson C, Rennie PS, Gleave ME: Overexpression of
insulin-like growth factor binding protein-5 helps accelerate
progression to androgen-independence in the human pros-
tate LNCaP tumor model through activation of phosphati-
dylinositol 3'-kinase pathway.  Endocrinology 2000,
141:2257-2265.
91. Lin J, Adam RM, Santiestevan E, Freeman MR: The phosphatidyli-
nositol 3'-kinase pathway is a dominant growth factor- acti-
vated cell survival pathway in LNCaP human prostate
carcinoma cells. Cancer Res 1999, 59:2891-2897.
92. Murillo H, Huang H, Schmidt LJ, Smith DI, Tindall DJ: Role of PI3K
signaling in survival and progression of LNCaP prostate can-
cer cells to the androgen refractory state. Endocrinology 2001,
142:4795-4805.
93. Yang L, Wang L, Lin HK, Kan PY, Xie S, Tsai MY, Wang PH, Chen YT,
Chang C: Interleukin-6 differentially regulates androgen
receptor transactivation via PI3K-Akt, STAT3, and MAPK,
three distinct signal pathways in prostate cancer cells. Bio-
chem Biophys Res Commun 2003, 305:462-469.
94. Beresford SA, Davies MA, Gallick GE, Donato NJ: Differential
effects of phosphatidylinositol-3/Akt-kinase inhibition on
apoptotic sensitization to cytokines in LNCaP and PCc-3
prostate cancer cells. J Interferon Cytokine Res 2001, 21:313-322.
95. Downward J: Mechanisms and consequences of activation of
protein kinase B/Akt. Curr Opin Cell Biol 1998, 10:262-267.
96. Sonoda Yoshiko, Watanbe Shiro, Matsumoto Yaeko, Aizu-Yokota
Eriko, Kasahara Tadashi: FAK is the upstream signal protein of
the phosphatidylinositol 3-kinase-Akt survival pathway in
hydrogen peroxide-induced apoptosis of a human glioblast-
oma cell line. Journal of Biological Chemistry 1999, 274:10566-10570.
97. Kostenuik PJ, Sanchez-Sweatman O, Orr FW, Singh G: Bone cell
matrix promotes the adhesion of human prostatic carci-
noma cells via the alpha 2 beta 1 integrin. Clin Exp Metastasis
1996, 14:19-26.
98. Festuccia C, Bologna M, Gravina GL, Guerra F, Angelucci A, Villanova
I, Millimaggi D, Teti A: Osteoblast conditioned media contain
TGF-beta1 and modulate the migration of prostate tumor
cells and their interactions with extracellular matrix
components. Int J Cancer 1999, 81:395-403.
99. Stamenkovic I: Matrix metalloproteinases in tumor invasion
and metastasis. Semin Cancer Biol 2000, 10:415-433.
100. Rigg AS, Lemoine NR: Adenoviral delivery of TIMP1 or TIMP2
can modify the invasive behavior of pancreatic cancer and
can have a significant antitumor effect in vivo. Cancer Gene Ther
2001, 8:869-878.
101. Del Rosso M, Fibbi G, Pucci M, D'Alessio S, Del Rosso A, Magnelli L,
Chiarugi V: Multiple pathways of cell invasion are regulated by
multiple families of serine proteases. Clin Exp Metastasis 2002,
19:193-207.
102. Nemeth JA, Harb JF, Barroso U., Jr., He Z, Grignon DJ, Cher ML:
Severe combined immunodeficient-hu model of human
prostate cancer metastasis to human bone. Cancer Res 1999,
59:1987-1993.
103. Nemeth JA, Yousif R, Herzog M, Che M, Upadhyay J, Shekarriz B,
Bhagat S, Mullins C, Fridman R, Cher ML: Matrix metalloprotein-
ase activity, bone matrix turnover, and tumor cell prolifera-
tion in prostate cancer bone metastasis. J Natl Cancer Inst 2002,
94:17-25.
104. Lichtinghagen R, Musholt PB, Lein M, Romer A, Rudolph B, Kris-
tiansen G, Hauptmann S, Schnorr D, Loening SA, Jung K: Different
mRNA and protein expression of matrix metalloproteinases
2 and 9 and tissue inhibitor of metalloproteinases 1 in benign
and malignant prostate tissue. Eur Urol 2002, 42:398-406.
105. Nagakawa O, Murakami K, Yamaura T, Fujiuchi Y, Murata J, Fuse H,
Saiki I: Expression of membrane-type 1 matrix metalloprotei-
nase (MT1-MMP) on prostate cancer cell lines.  Cancer Lett
2000, 155:173-179.
106. Usmani BA, Shen R, Janeczko M, Papandreou CN, Lee WH, Nelson
WG, Nelson JB, Nanus DM: Methylation of the neutral
endopeptidase gene promoter in human prostate cancers.
Clin Cancer Res 2000, 6:1664-1670.
107. Li Z, Hou WS, Bromme D: Collagenolytic activity of cathepsin
K is specifically modulated by cartilage-resident chondroitin
sulfates. Biochemistry 2000, 39:529-536.
108. Bonnefoy A, Legrand C: Proteolysis of subendothelial adhesive
glycoproteins (fibronectin, thrombospondin, and von Wille-
brand factor) by plasmin, leukocyte cathepsin G, and
elastase. Thromb Res 2000, 98:323-332.
109. Ioachim E, Kamina S, Kontostolis M, Agnantis NJ: Immunohisto-
chemical expression of cathepsin D in correlation with extra-
cellular matrix component, steroid receptor status and
proliferative indices in breast cancer.  Virchows Arch 1997,
431:311-316.
110. Fernandez PL, Farre X, Nadal A, Fernandez E, Peiro N, Sloane BF, Shi
GP, Chapman HA, Campo E, Cardesa A: Expression of cathepsins
B and S in the progression of prostate carcinoma. Int J Cancer
2001, 95:51-55.
111. Sinha AA, Quast BJ, Wilson MJ, Fernandes ET, Reddy PK, Ewing SL,
Sloane BF, Gleason DF: Ratio of cathepsin B to stefin A identi-
fies heterogeneity within Gleason histologic scores for
human prostate cancer. Prostate 2001, 48:274-284.
112. Brubaker KD, Vessella RL, True LD, Thomas R, Corey E: Cathepsin
K mRNA and protein expression in prostate cancer
progression. J Bone Miner Res 2003, 18:222-230.
113. Thalmann GN, Sikes RA, Wu TT, Degeorges A, Chang SM, Ozen M,
Pathak S, Chung LW: LNCaP progression model of human
prostate cancer: androgen-independence and osseous
metastasis. Prostate 2000, 44:91-103 Jul 1;44(2)..
114. Miles LA, Dahlberg CM, Plescia J, al. et: Role of cell-surface lysines
in plasminogen binding to cells: Identification of alpha eno-
lase as a candidate plasminogen receptor. .
115. Andreasen PA, Egelund R, Petersen HH: The plasminogen activa-
tion system in tumor growth, invasion, and metastasis. Cell
Mol Life Sci 2000, 57:25-40.
116. Hoosein NM, Boyd DD, Hollas WJ, Mazar A, Henkin J, Chung LW:
Involvement of urokinase and its receptor in the invasiveness
of human prostatic carcinoma cell lines. Cancer Commun 1991,
3:255-264.
117. Xing RH, Rabbani SA: Regulation of urokinase production by
androgens in human prostate cancer cells: effect on tumor
growth and metastases in vivo.  Endocrinology 1999,
140:4056-4064.Reproductive Biology and Endocrinology 2004, 2 http://www.rbej.com/content/2/1/2
Page 12 of 13
(page number not for citation purposes)
118. Festuccia C, Dolo V, Guerra F, Violini S, Muzi P, Pavan A, Bologna M:
Plasminogen activator system modulates invasive capacity
and proliferation in prostatic tumor cells. Clin Exp Metastasis
1998, 16:513-528.
119. Chapman HA: Plasminogen activators, integrins, and the coor-
dinated regulation of cell adhesion and migration. Curr Opin
Cell Biol 1997, 9:714-724.
120. Chapman HA, Wei Y, Simon DI, Waltz DA: Role of urokinase
receptor and caveolin in regulation of integrin signaling.
Thromb Haemost 1999, 82:291-297.
121. Ossowski L, Aguirre-Ghiso JA: Urokinase receptor and integrin
partnership: coordination of signaling for cell adhesion,
migration and growth. Curr Opin Cell Biol 2000, 12:613-620.
122. Mainiero F, Pepe A, Yeon M, Ren Y, Giancotti FG: The intracellular
functions of alpha6beta4 integrin are regulated by EGF. J Cell
Biol 1996, 134:241-253.
123. Ridley AJ, Hall A: The small GTP-binding protein rho regulates
the assembly of focal adhesions and actin stress fibers in
response to growth factors. Cell 1992, 70:389-399.
124. Nagle RB, Knox JD, Wolf C, Bowden GT, Cress AE: Adhesion mol-
ecules, extracellular matrix, and proteases in prostate
carcinoma. J Cell Biochem Suppl 1994, 19:232-237.
125. Dedhar S, Saulnier R, Nagle R, Overall CM: Specific alterations in
the expression of alpha 3 beta 1 and alpha 6 beta 4 integrins
in highly invasive and metastatic variants of human prostate
carcinoma cells selected by in vitro invasion through recon-
stituted basement membrane.  Clin Exp Metastasis 1993,
11:391-400.
126. Witkowski Colette M., Rabinovitz Isaac, Nagle Raymmond B., Affinito
Kit-Sahn D., Cress Anne E.: Characterization of integrin subu-
nits, cellular adhesion and tumorgenicity of four human
prostate cell lines. J Cancer Res Clin Oncol 1993, 119:637-644.
127. Hughes PE, Pfaff M: Integrin affinity modulation. Trends Cell Biol
1998, 8:359-364.
128. Elices MJ, Hemler ME: The human integrin VLA-2 is a collagen
receptor on some cells and a collagen/laminin receptor on
others. Proc Natl Acad Sci U S A 1989, 86:9906-9910.
129. O'Toole TE, Mandelman D, Forsyth J, Shattil SJ, Plow EF, Ginsberg
MH: Modulation of the affinity of integrin alpha IIb beta 3
(GPIIb-IIIa) by the cytoplasmic domain of alpha IIb. Science
1991, 254:845-847.
130. Sims PJ, Ginsberg MH, Plow EF, Shattil SJ: Effect of platelet activa-
tion on the conformation of the plasma membrane glycopro-
tein IIb-IIIa complex. J Biol Chem 1991, 266:7345-7352.
131. Clark EA, Brugge JS: Integrins and signal transduction path-
ways: the road taken. Science 1995, 268:233-239.
132. Burridge K, Chrzanowska-Wodnicka M: Focal adhesions, contrac-
tility, and signaling. Annu Rev Cell Dev Biol 1996, 12:463-518.
133. Schoenwaelder SM, Burridge K: Bidirectional signaling between
the cytoskeleton and integrins.  Curr Opin Cell Biol 1999,
11:274-286.
134. Chung LW, Davies R: Prostate epithelial differentiation is dic-
tated by its surrounding stroma. Mol Biol Rep 1996, 23:13-19.
135. Giancotti FG, Ruoslahti E: Integrin signaling.  Science 1999,
285:1028-1032.
136. DiPersio CM, Hodivala-Dilke KM, Jaenisch R, Kreidberg JA, Hynes
RO: alpha3beta1 Integrin is required for normal develop-
ment of the epidermal basement membrane. J Cell Biol 1997,
137:729-742.
137. Rabinovitz I, Cress AE, Nagle RB: Biosynthesis and secretion of
laminin and S-laminin by human prostate carcinoma cell
lines. Prostate 1994, 25:97-107.
138. Calof AL, Campanero MR, O'Rear JJ, Yurchenco PD, Lander AD:
Domain-specific activation of neuronal migration and neur-
ite outgrowth- promoting activities of laminin. Neuron 1994,
13:117-130.
139. Giannelli G, Falk-Marzillier J, Schiraldi O, Stetler-Stevenson WG,
Quaranta V: Induction of cell migration by matrix metallopro-
tease-2 cleavage of laminin-5. Science 1997, 277:225-228.
140. Cooper Carlton R., Sikes Robert A., Nicholson Brian E., Sun Yan-Xi,
Pienta Kenneth J., Taichman Russell S.: Cancer cells homing to
bone: the significance of chemotaxis and cell adhesion. The
biology of skeletal metastases Edited by: Evan Keller and Leland WChung.
Kluwer Academic Publishers-in press; 2003. 
141. Liapis H, Adler LM, Wick MR, Rader JS: Expression of
alpha(v)beta3 integrin is less frequent in ovarian epithelial
tumors of low malignant potential in contrast to ovarian
carcinomas. Hum Pathol 1997, 28:443-449.
142. Stromblad S, Becker JC, Yebra M, Brooks PC, Cheresh DA: Sup-
pression of p53 activity and p21WAF1/CIP1 expression by
vascular cell integrin alphaVbeta3 during angiogenesis. J Clin
Invest 1996, 98:426-433.
143. Elgavish A, Prince C, Chang PL, Lloyd K, Lindsey R, Reed R: Oste-
opontin stimulates a subpopulation of quiescent human
prostate epithelial cells with high proliferative potential to
divide in vitro. Prostate 1998, 35:83-94.
144. Marengo SR, Sikes RA, Anezinis P, Chang SM, Chung LW: Metastasis
induced by overexpression of p185neu-T after orthotopic
injection into a prostatic epithelial cell line (NbE). Mol Carcinog
1997, 19:165-175.
145. Sikes RA, Chung LW: Acquisition of a tumorigenic phenotype
by a rat ventral prostate epithelial cell line expressing a
transfected activated neu oncogene.  Cancer Res 1992,
52:3174-3181.
146. Chung LW, Chang SM, Bell C, Zhau H, Ro JY, von Eschenbach AC:
Prostatic carcinogenesis evoked by cellular interaction. Envi-
ron Health Perspect 1988, 77:23-28.
147. Chung LW, Chang SM, Bell C, Zhau HE, Ro JY, von Eschenbach AC:
Co-inoculation of tumorigenic rat prostate mesenchymal
cells with non-tumorigenic epithelial cells results in the
development of carcinosarcoma in syngeneic and athymic
animals. Int J Cancer 1989, 43:1179-1187.
148. Bae VL, Jackson-Cook CK, Brothman AR, Maygarden SJ, Ware JL:
Tumorigenicity of SV40 T antigen immortalized human
prostate epithelial cells: association with decreased epider-
mal growth factor receptor (EGFR) expression. Int J Cancer
1994, 58:721-729.
149. Bae VL, Jackson-Cook CK, Maygarden SJ, Plymate SR, Chen J, Ware
JL: Metastatic sublines of an SV40 large T antigen immortal-
ized human prostate epithelial cell line.  Prostate 1998,
34:275-282.
150. Stone KR, Mickey DD, Wunderli H, Mickey GH, Paulson DF: Isola-
tion of a human prostate carcinoma cell line (DU 145). Inter-
national Journal of Cancer 1978, 21:274-281.
151. Horoszewicz JS, Leong SS, Chu TM, Wajsman ZL, Friedman M, Papsi-
dero L, Kim U, Chai LS, Kakati S, Arya SK, Sandberg AA: The
LNCaP cell line-a new model for studies on human prostatic
carcinoma.  Progress in Clinical & Biological Research 1980,
37:115-132.
152. Korenchuk S, Lehr JE, L M. Clean, Lee YG, Whitney S, Vessella R, Lin
DL, Pienta KJ: VCaP, a cell-based model system of human
prostate cancer. In Vivo 2001, 15:163-168.
153. Kaighn ME, Narayan KS, Ohnuki Y, Lechner JF, Jones LW: Establish-
ment and characterization of a human prostatic carcinoma
cell line (PC-3). Investigative Urology 1979, 17:16-23.
154. Rios-Doria Jonathan, Day Kathleen C., Kuefer Rainer, Rashid Michael
G., Chinnaiyan Arul M., Rubin Mark A., Day Mark L.: The Role of
Calpain in the Proteolytic Cleavage of E-cadherin in Prostate
and Mammary Epithelial Cells. The Journal Of Biological Chemistry
2003, 278:1372-1379.
155. Usmani BA, Harden B, Maitland NJ, Turner AJ: Differential expres-
sion of neutral endopeptidase-24.11 (neprilysin) and
endothelin-converting enzyme in human prostate cancer
cell lines. Clin Sci (Lond) 2002, 103 Suppl 48:314S-317S..
156. Conover CA, Perry JE, Tindall DJ: Endogenous cathepsin D-
mediated hydrolysis of insulin-like growth factor-binding
proteins in cultured human prostatic carcinoma cells. J Clin
Endocrinol Metab 1995, 80:987-993.
157. Nunn SE, Peehl DM, Cohen P: Acid-activated insulin-like growth
factor binding protein protease activity of cathepsin D in
normal and malignant prostatic epithelial cells and seminal
plasma. J Cell Physiol 1997, 171:196-204.
158. Manes S, Llorente M, Lacalle RA, Gomez-Mouton C, Kremer L, Mira
E, Martinez AC: The matrix metalloproteinase-9 regulates the
insulin-like growth factor-triggered autocrine response in
DU-145 carcinoma cell. J Biol Chem 1999, 274:6935-6945.
159. Waltregny D, Bellahcene A, de Leval X, Florkin B, Weidle U, Cas-
tronovo V: Increased expression of bone sialoprotein in bone
metastases compared with visceral metastases in human
breast and prostate cancers. J Bone Miner Res 2000, 15:834-843.
160. Ylikoski A, Pettersson K, Nurmi J, Irjala K, Karp M, Lilja H, Lovgren
T, Nurmi M: Simultaneous quantification of prostate-specificPublish with BioMed Central    and   every 
scientist can read your work free of charge
"BioMed Central will be the most significant development for 
disseminating the results of biomedical research in our lifetime."
Sir Paul Nurse, Cancer Research UK
Your research papers will be:
available free of charge to the entire biomedical community
peer reviewed and published  immediately upon acceptance
cited in PubMed and archived on PubMed Central 
yours — you keep the copyright
Submit your manuscript here:
http://www.biomedcentral.com/info/publishing_adv.asp
BioMedcentral
Reproductive Biology and Endocrinology 2004, 2 http://www.rbej.com/content/2/1/2
Page 13 of 13
(page number not for citation purposes)
antigen and human glandular kallikrein 2 mRNA in blood
samples from patients with prostate cancer and benign
disease. Clin Chem 2002, 48:1265-1271.
161. Kanoh Y, Akahoshi T, Ohara T, Ohtani N, Mashiko T, Ohtani S, Egawa
S, Baba S: Expression of matrix metalloproteinase-2 and pros-
tate-specific antigen in localized and metastatic prostate
cancer. Anticancer Res 2002, 22:1813-1817.
162. Hashimoto K, Kihira Y, Matuo Y, Usui T: Expression of matrix
metalloproteinase-7 and tissue inhibitor of metalloprotein-
ase-1 in human prostate. J Urol 1998, 160:1872-1876.
163. Chambon M, Rebillard X, Rochefort H, Brouillet JP, Baldet P, Guiter
J, Maudelonde T: Cathepsin D cytosolic assay and immunohis-
tochemical quantification in human prostate tumors. Prostate
1994, 24:320-325.
164. Uria JA, Lopez-Otin C: Matrilysin-2, a new matrix metallopro-
teinase expressed in human tumors and showing the mini-
mal domain organization required for secretion, latency,
and activity. Cancer Res 2000, 60:4745-4751.